BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The company Glaxo Group Ltd submitted on 30 June 1995 an application for Marketing Authorisation 
to  the  EMEA  for  3TC  (later  EPIVIR)  tablets  150  mg  and  oral  solution  10  mg/ml,  through  the 
Centralised procedure. After agreement by the CPMP, this  medicinal product was referred to List B 
status in the Annex of the Council regulation EEC No. 2309/93, indent 7 as it contains a new active 
substance. 
The Rapporteur and the Co-rapporteur appointed by the CPMP were as follows: 
Rapporteur:  Dr. P. Le Courtois 
Co-Rapporteur: 
Prof. A. Hildebrandt 
Licensing status: 
EPIVIR has been approved in several non-EU countries including: 
USA on 17 November 1995, Canada on 11 December 1995, Australia on 29 February 1996 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The  Rapporteur’s  initial  assessment  report  was  circulated  to  all  CPMP  Members  on  
25 September 1995. 
The  Co-Rapporteur’s  initial  assessment  reports  were  circulated  to  all  CPMP  Members  on  
25 September 1995. 
During their November 1995  meeting the CPMP agreed on a consolidated list  of questions as 
prepared by  the Rapporteur and Co-Rapporteur. The  list  including comments  on the  proposed 
brand name was sent to the company on 24 November 1995, when the clock was stopped. 
A  preliminary  GCP  inspection  report,  prepared  by  the  French  competent  authorities,  was 
circulated  during  the  CPMP  December  1995  meeting.  Questions  on  the  biological  database 
were  raised  during  this  inspection.  The  Rapporteur  requested  the  company  to  provide  an 
explanation before the clock could be re-started. 
During the CPMP meeting in January 1996, the new proposed brand name for the product was 
announced: EPIVIR. 
The company submitted their responses to the consolidated list of questions on Parts II and III 
on 31 January 1996. 
A  final  GCP  inspection  report,  by  the  French  competent  authorities,  was  circulated  on  
20 February 1996. 
The company submitted their responses to the consolidated list of questions on Parts I and IV on 
7 March 1996. 
The Rapporteur and Co-Rapporteur’s joint assessment report on the company’s responses was 
circulated to all CPMP Members on 22 March 1996. 
On 22 March 1996 the company submitted additional stability data for the oral solution. 
The Rapporteur’s additional assessment report was circulated on 15 April 1996. 
During its meeting in April 1996, the CPMP discussed the recommendations presented by the 
Rapporteur  and  Co-Rapporteur.  A  hearing  with  the  company  took  place  on  17  April  1996,  to 
address the final outstanding issues. 
On 17 April 1996 the company submitted to the EMEA their letter of commitment to provide, 
within the specific time frame, the results of the additional studies. 
1/2 
EMEA 2005 
 
 
 
 
 
In light of the overall data submitted and the scientific discussion within the Committee, the CPMP 
issued a positive Opinion for granting a Marketing Authorisation, under exceptional circumstances, 
for the two different oral presentations of EPIVIR, on 18 April 1996. The CPMP Opinions were 
forwarded, in all official languages of the European Union, to the European Commission which 
adopted the corresponding Decisions on 8 August 1996. 
2/2 
EMEA 2005 
 
 
 
 
 
 
 
